LGALS3 and ischemic cardiomyopathy: It has been shown that Galectin-3 measured after STEMI is an independent predictor of increased ECV at 6 months [31]; it is also associated with myocardial replacement fibrosis assessed by LGE in patients with non-ischemic cardiomyopathy [32].